Actinium
ATNM
Actinium (ATNM) news
Recent news
Actinium Pharmaceuticals announces oral presentation at EANM 2026 highlighting first-in-human phase 1 study of Atnm-400, a non-PSMA targeting radiotherapy, in prostate cancer
AInvest Wire · 6h agoActinium Pharmaceuticals names Matt David as CFO
AInvest Wire · 7h agoActinium Pharmaceuticals strengthens leadership team with appointment of Matt David, M.D. as chief financial officer
AInvest Wire · 7h agoActinium Pharmaceuticals - amends IND to add manufacturer for CRADA and company studies; milestones expected H2 2026-2027
AInvest Wire · Aug 14, 2026Actinium Pharmaceuticals announces Actimab-A intellectual property and manufacturing advances and provides NYSE American listing update
AInvest Wire · Aug 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.